Page last updated: 2024-08-17

quinoxalines and hby 097

quinoxalines has been researched along with hby 097 in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's15 (75.00)18.2507
2000's4 (20.00)29.6817
2010's1 (5.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arnold, E; Hsiou, Y; Kirsch, R; Kleim, JP; Paessens, A; Riess, G; Rösner, M; Winkler, I1
Bender, R; Kaiser, R; Kirsch, R; Kleim, JP; Meichsner, C; Paessens, A; Rösner, M; Rübsamen-Waigmann, H; Schneweis, KE; Wichers, M1
Kirsch, R; Kleim, JP; Paessens, A; Riess, G; Rösner, M; Rübsamen-Waigmann, H; Winkler, I1
Huguenel, E; Kleim, JP; Paessens, A; Rübsamen-Waigmann, H; Shah, A; Wainberg, MA1
Balzarini, J; De Clercq, E; Kleim, JP; Pelemans, H; Riess, G; Roesner, M; Winkler, I2
Agarwal, VK; Krol, GJ; Krone, V; Roberts, D1
Arnold, E; Clark, AD; Das, K; Ding, J; Hsiou, Y; Hughes, SH; Kleim, JP; Riess, G; Rösner, M; Winkler, I1
Balzarini, J; Dunkler, A; Kleim, JP; Merigan, TC; Oette, D; Riess, G; Suarez, JR; Winkler, I; Winters, M1
Dietrich, U; Huguenel, E; Immelmann, A; Paessens, A; Rübsamen-Waigmann, H; Ruoff, HJ; Shah, A; von Briesen, H; Wainberg, MA1
Aweeka, F; Hayashi, S; Jayesekera, D; Jayewardene, A; Shah, A; Thevanayagam, L1
Balzarini, J; De Clercq, E; Desmyter, J; Esnouf, R; Kleim, JP; Pannecouque, C; Schmit, JC; Van Laethem, K; Van Remoortel, B; Vandamme, AM; Witvrouw, M1
Pieribone, V1
Arnold, E; Boyer, PL; Clark, AD; Das, K; Ding, J; Hsiou, Y; Hughes, SH; Janssen, PA; Kleim, JP; Lewi, P; Rösner, M1
Arnold, E; Boyer, PL; Clark, AD; Das, K; Hughes, SH; Sarafianos, SG1
Manallack, DT1
Coluccia, A; La Regina, G; Silvestri, R1

Reviews

1 review(s) available for quinoxalines and hby 097

ArticleYear
Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
    Antiviral chemistry & chemotherapy, 2010, Aug-11, Volume: 20, Issue:6

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Binding Sites; Cell Line; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Models, Molecular; Molecular Conformation; Nitriles; Phosphinic Acids; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; Quinoxalines; Reverse Transcriptase Inhibitors; Rilpivirine

2010

Trials

5 trial(s) available for quinoxalines and hby 097

ArticleYear
Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load.
    Lancet (London, England), 1997, May-24, Volume: 349, Issue:9064

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiviral Agents; Cohort Studies; Double-Blind Method; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Mutation; Placebos; Quinoxalines; Reverse Transcriptase Inhibitors; Viral Load; Viremia; Virus Replication

1997
Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.
    The Journal of infectious diseases, 1999, Volume: 179, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Quinoxalines; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Zidovudine

1999
Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro.
    Antiviral research, 1999, Volume: 42, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Genotype; HIV Infections; HIV-1; Humans; Mutation; Phenotype; Quinoxalines; Reverse Transcriptase Inhibitors; Viral Load

1999
Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients.
    Journal of clinical pharmacology, 1999, Volume: 39, Issue:10

    Topics: Adult; Antiviral Agents; Area Under Curve; Drug Interactions; Drug Therapy, Combination; Exanthema; Female; Gastrointestinal Diseases; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Middle Aged; Quinoxalines; Reverse Transcriptase Inhibitors; Zidovudine

1999
Los Angeles, New York, Stanford University: HBY 097, new drug may weaken HIV.
    AIDS treatment news, 1995, Oct-06, Issue:no 232

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV; HIV Reverse Transcriptase; Humans; Los Angeles; Mutation; New York; Quinoxalines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; San Francisco

1995

Other Studies

14 other study(ies) available for quinoxalines and hby 097

ArticleYear
[New substance against AIDS in clinical trial].
    Fortschritte der Medizin, 1995, Feb-10, Volume: 113, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials, Phase I as Topic; HIV Reverse Transcriptase; Humans; Quinoxalines; Reverse Transcriptase Inhibitors

1995
Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Le
    Proceedings of the National Academy of Sciences of the United States of America, 1996, Jan-09, Volume: 93, Issue:1

    Topics: Antiviral Agents; Base Sequence; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Molecular Sequence Data; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Selection, Genetic; Virus Replication

1996
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.
    Antimicrobial agents and chemotherapy, 1995, Volume: 39, Issue:10

    Topics: Animals; Antiviral Agents; Base Sequence; Dogs; Drug Resistance; Female; HIV-1; Humans; Mice; Molecular Sequence Data; Quinoxalines; Reverse Transcriptase Inhibitors; Virus Replication

1995
In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.
    Virology, 1997, Apr-28, Volume: 231, Issue:1

    Topics: Antiviral Agents; Drug Resistance, Microbial; Genotype; HIV Reverse Transcriptase; Humans; Molecular Structure; Mutation; Phenotype; Quinoxalines; Reverse Transcriptase Inhibitors

1997
Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.
    The Journal of infectious diseases, 1997, Volume: 176, Issue:5

    Topics: Anti-HIV Agents; Antiviral Agents; Cells, Cultured; Drug Resistance; HIV-1; Humans; Lamivudine; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; Zidovudine

1997
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined
    Biochemical pharmacology, 1998, Mar-01, Volume: 55, Issue:5

    Topics: Anti-HIV Agents; Antiviral Agents; Benzodiazepines; Cell Line; Delavirdine; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Quinoxalines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine

1998
Quantitative analysis of HBY 097 and its metabolites in human serum and urine by HPLC.
    Journal of pharmaceutical and biomedical analysis, 1998, Volume: 16, Issue:7

    Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Humans; Models, Chemical; Quinoxalines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity

1998
Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
    Journal of molecular biology, 1998, Nov-27, Volume: 284, Issue:2

    Topics: Antiviral Agents; Crystallography, X-Ray; Drug Design; Drug Resistance; Glutamic Acid; Glycine; HIV Reverse Transcriptase; Leucine; Models, Molecular; Molecular Conformation; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; Tyrosine

1998
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
    AIDS (London, England), 2001, Mar-30, Volume: 15, Issue:5

    Topics: Anti-HIV Agents; Antiviral Agents; Binding Sites; Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nucleosides; Phenotype; Quinoxalines; Reverse Transcriptase Inhibitors

2001
Overcoming resistance to reverse transcriptase inhibitors.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:9

    Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Microbial; HIV; Humans; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; RNA, Viral; Virus Replication

1995
New type of HIV drug.
    Treatment review, 1995, Issue:no 20

    Topics: Antiviral Agents; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Quinoxalines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase

1995
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Journal of molecular biology, 2001, Jun-01, Volume: 309, Issue:2

    Topics: Acetamides; Acetophenones; Amino Acid Substitution; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Drug Design; Drug Resistance, Microbial; Enzyme Stability; HIV Reverse Transcriptase; HIV-1; Hydrogen Bonding; Ligands; Models, Molecular; Mutation, Missense; Protein Conformation; Protein Subunits; Quinoxalines; Reverse Transcriptase Inhibitors; Thermodynamics

2001
Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
    Journal of molecular biology, 2007, Jan-05, Volume: 365, Issue:1

    Topics: Adenosine Triphosphate; Amino Acid Substitution; Anti-HIV Agents; Binding Sites; Crystallography, X-Ray; DNA; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Manganese; Models, Molecular; Molecular Conformation; Mutation; Protein Conformation; Quinoxalines; Reverse Transcriptase Inhibitors

2007
The use of local surface properties for molecular superimposition.
    Journal of molecular modeling, 2008, Volume: 14, Issue:9

    Topics: Amino Acid Chloromethyl Ketones; Anti-HIV Agents; Anticoagulants; Antimetabolites, Antineoplastic; Crystallography, X-Ray; Dipeptides; Folic Acid; HIV Protease Inhibitors; Humans; Imidazoles; Ligands; Methotrexate; Models, Molecular; Molecular Structure; Piperidines; Protein Binding; Proteins; Quinoxalines; Reverse Transcriptase Inhibitors; Software; Static Electricity; Structure-Activity Relationship; Sulfur Compounds; Surface Properties; Tetrahydrofolate Dehydrogenase

2008